SAN DIEGO, Jan. 3, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. will be presenting at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 10, 2011 at 4:30 p.m. ET / 1:30 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
The presentation and break-out session will be webcast through the "Investors" section of Amylin's corporate website at http://www.amylin.com/, and a recording will be made available following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at http://www.amylin.com/.
Amylin Pharmaceuticals, Inc.
CONTACT: Michael York, Senior Director, Investor Relations,
+1-858-552-2200 ext. 8602, or Anne Erickson, Senior Director, Corporate
Affairs, +1-858-552-2200 ext. 4443, both of Amylin Pharmaceuticals, Inc.
Web Site: http://www.amylin.com/
